Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain

Gustavo C Machado,Christina Abdel-Shaheed,Martin Underwood,Richard O Day

DOI: https://doi.org/10.1136/bmj.n104

2021-01-29

BMJ

Abstract:<p>What you need to knowOral non-steroidal anti-inflammatory drugs (NSAIDs) can reduce musculoskeletal pain but increase the risk of gastrointestinal (perforation, ulcers, bleeding), cardiovascular...</p>

What problem does this paper attempt to address?

NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future

David Y. Graham,Francis K.L. Chan

DOI: https://doi.org/10.1053/j.gastro.2008.02.007

IF: 29.4

2008-01-01

Gastroenterology

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most widely used drugs. Each year, >111,000,000 prescriptions for NSAIDs were prescribed in the United States at a cost of $5 billion. Furthermore, there is an additional $2 billion spent on over-the-counter (OTC) NSAIDs.1 NSAIDs are primarily used for reducing the pain, disability, and reduced quality of life associated with pain and inflammation.2,3 In addition, aspirin is used for prevention of cardiovascular events.4 Both NSAIDs and aspirin are disproportionately used among the elderly and about one third of individuals aged ≥65 years have been reported to take NSAIDs on a daily basis, and 70% use them at least once a week.
Being on nonsteroidal anti-inflammatory drugs

neville d yeomans,francis k l chan

DOI: https://doi.org/10.1002/9781118321386.ch23

2015-01-01

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs), including low-dose aspirin, are very frequently prescribed in older patients in order to palliate or prevent age-related degenerative joint diseases or cardiovascular events. From the perspective of the gastrointestinal system, their most frequent serious adverse effect is hemorrhage from gastric or duodenal ulcers, occurring overall in about 0.5–2.0% per patient year of continuous use. Much more common are gastric erosions – at least a few will be found in most patients if an endoscopy is performed – but these usually heal uneventfully and are normally asymptomatic. Dyspepsia is a common side-effect but there is little correlation with the macroscopic injury and the pathogenetic mechanisms are less well understood. NSAIDs that are selective inhibitors of the cyclooxygenase-2 isozyme are fulfilling their promise of causing less ulceration and ulcer complications. However, the weight of evidence now suggests they increase the rate of myocardial infarction during prolonged use. Whether this risk is greater than with nonselective NSAIDs is currently under intensive investigation.
Primer: Managing NSAID-induced Ulcer Complications—balancing Gastrointestinal and Cardiovascular Risks

Francis K L Chan

DOI: https://doi.org/10.1038/ncpgasthep0610

2006-01-01

Abstract:Ulcer complications associated with the use of NSAIDs, in high-risk patients, are often caused by a failure to identify patients' risk factors, concomitant use of aspirin or multiple NSAIDs, and underutilization of gastroprotective agents. Current data suggest that cyclo-oxygenase 2 (COX2) inhibitors and some nonselective NSAIDs increase the risk of myocardial infarction. Physicians must, therefore, take into account both the gastrointestinal and the cardiovascular risks of individual patients when prescribing NSAIDs. In patients with a low cardiovascular risk, NSAIDs can be prescribed according to the level of gastrointestinal risk. Patients with a moderate gastrointestinal risk (one or two risk factors) should receive a COX2 inhibitor or an NSAID plus a PPI or misoprostol. Patients with more than two gastrointestinal risk factors or prior ulcer complications require the combination of a COX2 inhibitor and a PPI. Patients with a high cardiovascular risk (e.g. coronary heart disease or an estimated 10-year cardiovascular risk greater than 10%) should receive prophylactic aspirin and combination therapy with a PPI or misoprostol irrespective of the presence of gastrointestinal risk factors. Naproxen is the preferred NSAID because it is not associated with excess cardiovascular risk. Patients with a high cardiovascular risk and a very high gastrointestinal risk should avoid using NSAIDs or COX2 inhibitors.
Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations

Cheuk-Chun Szeto,Kentaro Sugano,Ji-Guang Wang,Kazuma Fujimoto,Samuel Whittle,Gopesh K Modi,Chen-Huen Chen,Jeong-Bae Park,Lai-Shan Tam,Kriengsak Vareesangthip,Kelvin K F Tsoi,Francis K L Chan

DOI: https://doi.org/10.1136/gutjnl-2019-319300

IF: 24.5

Gut

Abstract:Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most commonly prescribed medications, but they are associated with a number of serious adverse effects, including hypertension, cardiovascular disease, kidney injury and GI complications. Objective: To develop a set of multidisciplinary recommendations for the safe prescription of NSAIDs. Methods: Randomised control trials and observational studies published before January 2018 were reviewed, with 329 papers included for the synthesis of evidence-based recommendations. Results: Whenever possible, a NSAID should be avoided in patients with treatment-resistant hypertension, high risk of cardiovascular disease and severe chronic kidney disease (CKD). Before treatment with a NSAID is started, blood pressure should be measured, unrecognised CKD should be screened in high risk cases, and unexplained iron-deficiency anaemia should be investigated. For patients with high cardiovascular risk, and if NSAID treatment cannot be avoided, naproxen or celecoxib are preferred. For patients with a moderate risk of peptic ulcer disease, monotherapy with a non-selective NSAID plus a proton pump inhibitor (PPI), or a selective cyclo-oxygenase-2 (COX-2) inhibitor should be used; for those with a high risk of peptic ulcer disease, a selective COX-2 inhibitor plus PPI are needed. For patients with pre-existing hypertension receiving renin-angiotensin system blockers, empirical addition (or increase in the dose) of an antihypertensive agent of a different class should be considered. Blood pressure and renal function should be monitored in most cases. Conclusion: NSAIDs are a valuable armamentarium in clinical medicine, but appropriate recognition of high-risk cases, selection of a specific agent, choice of ulcer prophylaxis and monitoring after therapy are necessary to minimise the risk of adverse events.
Management of the upper gastrointestinal adverse effect of non-steroid anti-inflammatory drugs

Guo Jin-sheng

DOI: https://doi.org/10.3969/j.issn.1672-3384.2012.03.002

2012-01-01

Abstract:Non-steroid anti-inflammatory drugs (NSAIDs) is a group of commonly prescribed drugs with anti-inflammatory, analgesic, antipyretic properties. They all have an effect on inhibiting cyclooxygenase (COX) activity and blocking inflammatory prostaglandins synthesis. Based on their selectivity on COX isoenzymes, they were categorized into non-selective COX inhibitors, selective and highly selective COX-2 inhibitors. The clinical usage of NSAIDs may induce gastrointestinal adverse effect to varying degrees, and is one of the major causes of peptic ulcer and upper gastrointestinal bleeding in the patients, especially the high-risk population. In addition, some of the NSAIDs may increase the risk of cardiovascular events including acute myocardial infarction and stroke. The selection of NSAIDs and the prevention of their adverse effects have significant clinical and economic importance. NSAIDs should be administrated to appropriate and obligatory patients, with the minimum dosage and duration, and avoid being used in combination. Long-term administration should be limited to those patients that intolerant to other types of analgesia and compliant with frequent follow-up. For those patients with high risk of gastrointestinal adverse effects of NSAIDs, the selection of drugs should refer to current guideline for NSAIDs use and take preventing measures.
Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective

Samik Bindu,Somnath Mazumder,Uday Bandyopadhyay

DOI: https://doi.org/10.1016/j.bcp.2020.114147

IF: 6.1

2020-10-01

Biochemical Pharmacology

Abstract:<p>Owing to the efficacy in reducing pain and inflammation non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most popularly used medicines, confirming their position in the WHO's Model List of Essential Medicines. With escalating musculoskeletal complications, as evident from 2016 Global Burden of Disease data, NSAID usage is evidently unavoidable. Apart from analgesic, anti-inflammatory and antipyretic efficacies, NSAIDs are further documented to offer protection against diverse critical disorders including cancer and heart attacks. However, data from multiple placebo-controlled trials and meta-analyses studies alarmingly signify the adverse effects of NSAIDs in gastrointestinal, cardiovascular, hepatic, renal, cerebral and pulmonary complications. Although extensive research has elucidated the mechanisms underlying the clinical hazards of NSAIDs, no review has extensively collated the outcomes on various multiorgan toxicities of these drugs together. In this regard, the present review provides a comprehensive insight of the existing knowledge and recent developments on NSAID-induced organ damage. It precisely encompasses the current understanding of structure, classification and mode of action of NSAIDs while reiterating on the emerging instances of NSAID drug repurposing along with pharmacophore modification aimed at safer usage of NSAIDs where toxic effects are tamed without compromising the clinical benefits. The review does not intend to vilify these 'wonder drugs'; rather provide a careful understanding of their side-effects which would be beneficial in evaluating the risk-benefit threshold while rationally using NSAIDs at safer dose and duration.</p>

pharmacology & pharmacy
Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Francis K. L. Chan,Neena S. Abraham,James M. Scheiman,Loren Laine

DOI: https://doi.org/10.1111/j.1572-0241.2008.02200.x

2008-01-01

Abstract:BACKGROUND: Prescribing nonsteroidal antiinflammatory drugs (NSAIDs) is challenging because physicians have to consider gastrointestinal (GI) and cardiovascular (CV) safety issues.OBJECTIVE: The purpose of the study was to determine appropriate NSAID treatment strategies based on different combinations of GI and CV risks.METHODS: The working party comprised a multidisciplinary international panel of 19 experts. Two hundred eighty-eight vignettes were evaluated for the appropriateness of each of six options: naproxen, non-naproxen nonselective NSAIDs, naproxen plus proton pump inhibitor (PPI)/misoprostol, non-naproxen nonselective NSAID plus PPI/misoprostol, cyclooxygenase-2 selective NSAID (coxib), or coxib plus PPI/misoprostol. Using a two-stage modified Delphi process, the panel anonymously ranked the appropriateness of each option from 1 (extremely inappropriate) to 9 (extremely appropriate). Vignettes were considered appropriate if >= 80% of all panelists' scores were 7-9 and inappropriate if >= 80% of all panelists' scores were 1-3.RESULTS: The panel rated nonselective NSAIDs as appropriate when the patient had average GI risk (< 70 yr of age; no prior upper GI event; no corticosteroids, antithrombotic agents, anticoagulants). In patients with GI risk factors, cotherapy with a PPI/misoprostol was appropriate. Either a nonselective NSAID or a coxib was rated appropriate in patients with average CV risk; naproxen was preferred in patients with high CV risk. None of the options was considered appropriate in patients with multiple GI risk factors and high CV risk.CONCLUSIONS: The initial choice of an NSAID (naproxen vs. others) relates to a patient's CV risk, and the need for therapy to decrease GI complications (PPI/misoprostol or coxibs) is determined by severity and number of GI risk factors.
Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI

LaForge, John M.,Urso, Kelsey,Day, Juan Martin,Bourgeois, Cade W.,Ross, Maggie M.,Ahmadzadeh, Shahab,Shekoohi, Sahar,Cornett, Elyse M.,Kaye, Adam M.,Kaye, Alan David

DOI: https://doi.org/10.1007/s12325-023-02481-6

2023-03-23

Advances in Therapy

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most common class of drugs utilized for a variety of disorders, including headaches, pain states, fever, and other common conditions. In recent years, a link between NSAIDs and adverse effects has been identified, including renal, heart, and liver disease, bleeding, and increased mortality. NSAID-mediated renal disease is associated with interference with the cyclooxygenase enzyme. Literature evaluating NSAID renal effects has indicated that a number of factors are associated with acute and chronic kidney injury (AKI). Early diagnosis can identify changes in renal function and allow for cessation of NSAID use, limiting the risk for long-term chronic renal disease and in some cases reversal of renal injury. Alternative medications should be considered in those patients identified with morbidity linked to NSAID use. Nephrotoxicity is increased in the elderly population and in hypovolemia, high dose exposure, use of vasoconstrictors such as calcineurin inhibitors, and use of renin–angiotensin–aldosterone system (RAAS) inhibitors or diuretics. Careful risk/benefit considerations from healthcare professionals can limit the incidence and degree of morbidity and mortality, including in NSAID-mediated renal disease. Selective NSAID cyclooxygenase-2 inhibitors also possess risks and therefore clinicians should always recommend short-term courses of this class of drugs versus long-term dosing because of the risk of morbidity and mortality. Given that these drugs are available over the counter as well by prescribing, clinicians must communicate the risks and benefits of NSAIDs and provide sound recommendations to their patients regarding use short and long term.

pharmacology & pharmacy,medicine, research & experimental
Non-steroidal anti-inflammatory drugs in sports medicine: guidelines for practical but sensible use

J A Paoloni,C Milne,J Orchard,B Hamilton

DOI: https://doi.org/10.1136/bjsm.2009.059980

Abstract:Introduction: Non-steroidal anti-inflammatory drugs (NSAID) are commonly used in sports medicine. NSAID have known anti-inflammatory, analgesic, antipyretic and antithrombotic effects, although their in-vivo effects in treating musculoskeletal injuries in humans remain largely unknown. NSAID analgesic action is not significantly greater than paracetamol for musculoskeletal injury but they have a higher risk profile, with side-effects including asthma exacerbation, gastrointestinal and renal side-effects, hypertension and other cardiovascular diseases. Discussion: The authors recommend an approach to NSAID use in sports medicine whereby simple analgesia is preferentially used when analgesia is the primary desired outcome. However, based both on the current pathophysiological understanding of most injury presentations and the frequency that inflammation may actually be a component of the injury complex, it is premature to suppose that NSAID are not useful to the physician managing sports injuries. The prescribing of NSAID should be cautious and both situation and pathology specific. Both dose and duration minimisation should be prioritized and combined with simple principles of protection, rest, ice, compression, elevation (PRICE), which should allow NSAID-sparing. NSAID use should always be coupled with appropriate physical rehabilitation. Conclusion: NSAID are probably most useful for treating nerve and soft-tissue impingements, inflammatory arthropathies and tenosynovitis. They are not generally indicated for isolated chronic tendinopathy, or for fractures. The use of NSAID in treating muscle injury is controversial. Conditions in which NSAID use requires more careful assessment include ligament injury, joint injury, osteoarthritis, haematoma and postoperatively.
Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

José Pedro Henriques Patrício,Jorge Pinto Pereira Barbosa,Rui Miguel Monteiro Ramos,Nuno Filipe Pimenta Antunes,Pedro Carlos Santos de Melo

DOI: https://doi.org/10.1007/s40261-013-0052-6

2013-01-22

Clinical Drug Investigation

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently used in clinical practice, and are considered a first-line option for pain management. However, non-selective NSAIDs (nsNSAIDs) and new generation NSAIDs named cyclo-oxygenase-2 inhibitors (coxibs) are very different from one another and their cardiovascular and gastrointestinal safety profiles may influence prescribing. This article resulted from a search of MEDLINE/Pubmed, Cochrane Library, Bandolier, Medscape and Trip database, up to June 2011. Key words included non-steroidal anti-inflammatory, coxib and safety, with the purpose of reviewing the gastrointestinal and cardiovascular safety issues of NSAIDS and the main aspects that differentiate both classes. Selective coxibs are associated with a more favourable gastrointestinal safety profile than nsNSAIDs. In terms of the risk of cardiovascular events, there seems to be a class effect for all NSAIDs with the possible exception of naproxen. The proper usage guidelines for NSAIDs detail the importance of risk factors for each patient in addition to the differences between classes. Patients with high cardiovascular or gastrointestinal risk should avoid using NSAIDs. These medications should be used at the minimum effective dose and for the shortest time possible in all patients.

pharmacology & pharmacy
Management of NSAID-associated peptic ulcer disease

Luigi Melcarne,Pilar García-Iglesias,Xavier Calvet

DOI: https://doi.org/10.1586/17474124.2016.1142872

2016-03-02

Abstract:Non-steroidal anti-inflammatory drug (NSAID) use increases the risk of gastrointestinal complications such as ulcers or bleeding. The presence of factors like advanced age, history of peptic ulcer, Helicobacter pylori infection and the use of anticoagulants or antiplatelet agents increase this risk further. COX-2 inhibitors and antisecretory drugs, particularly proton pump inhibitors, help to minimize the risk of gastrointestinal complications in high-risk patients. This review presents a practical approach to the prevention and treatment of NSAID-associated peptic ulcer disease and examines the new advances in the rational use of NSAIDs.

gastroenterology & hepatology
Pharmacoeconomics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Hilary A. Wynne,Mark Campbell

DOI: https://doi.org/10.2165/00019053-199303020-00004

1993-02-01

PharmacoEconomics

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate.In patients with RA, symptom relief through use of NSAIDs is firmly established, although it remains unclear whether they influence the course and outcome of the disease. For the average patient with RA taking NSAIDs, the attributable risk of hospitalisation with gastrointestinal problems related to NSAIDs is 1.3 to 1.6% annually and risk of death is 0.15%. Associations of therapy with risk are greatest with age, corticosteroid use and previous NSAID-related gastrointestinal adverse effects, and less marked with disability and high NSAID dose. These are important data in attempting to balance risk of therapy with clinical efficacy in an individual patient, and assessing the cost-effectiveness of prophylaxis.Although half of all NSAID consumption is for control of pain associated with degenerative conditions, their superiority over simple analgesics in osteoarthritis is poorly documented. This finding supports the use of the simple analgesic paracetamol (acetaminophen) as the preferred therapy of osteoarthritis, especially when its lower cost and low incidence of adverse effects are taken into consideration.Consistent differences in clinical effectiveness of individual NSAIDs have not been demonstrated, although unpredictable interpatient variation in response to individual agents is of considerable clinical importance, and a more expensive NSAID may prove cost effective for some patients. Cost effectiveness can be improved by a self-adjusted dosage regime which also leads to lower overall drug consumption. The adverse gastrointestinal effects of these drugs account for about 30% of the overall cost of arthritis treatment, and although studies to date have been too limited to assess the relative risk of gastrointestinal toxicity of the different NSAIDs reliably, ibuprofen appears to be one of the least hazardous, and azapropazone one of the most hazardous. Although the effectiveness of prophylaxis with H2-antagonists and with prostaglandin Ei analogues (prostaglandin-E1 analogues has been established, estimates of cost-benefit ratios are widely divergent. To establish the most cost-effective therapy with NSAIDs, more data are required to establish multivariable risk profiles for identification of patients at particular risk, the optimal drug, and its optimal dosage and duration of treatment. A more cost-effective use of NSAIDs could be achieved by a more thorough clinical assessment of efficacy in an individual patient which would lead to a lower overall use but greater therapeutic benefit.There is only limited evidence for the efficacy of NSAIDs in acute musculoskeletal disorders such as strains, sprains or sports injuries. There is no clear evidence of superiority among drugs, and no studies have yet examined the pharmacoeconomic aspects of their use compared with other effective treatment options.Although satisfactory cost-effectiveness data are not available for the use of NSAIDs in management of dysmenorrhoea, they are clinically effective (particularly ibuprofen, naproxen and mefenamic acid), and serious adverse effects are rare because of the short treatment periods. NSAIDs have limited efficacy in reducing blood loss in menorrhagia, and there is no clear evidence of superiority among agents. Pharmacoeconomic studies to support their cost effectiveness over other treatment options are not available.Indomethacin has a role as a preferred and cost-effective treatment for patent ductus arteriosus in the neonate, with surgery being used when drug therapy fails.Only limited data on the cost effectiveness of NSAIDs are available, despite their wide use. In part, this reflects the primarily clinical assessment of the effectiveness of treatments. The development of standardised and well validated assessment instruments is required. Such data as are available are sometimes from poorly designed studies. Future studies must include randomisation of treatments and blinding of participants to therapies wherever possible.

pharmacology & pharmacy,health care sciences & services,health policy & services,economics
The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment

Francis K. L. Chan

DOI: https://doi.org/10.1111/j.1572-0241.2007.01545.x

2008-01-01

Abstract:Recent evidence suggests that both cyclooxygenase-2 (COX-2) inhibitors and nonselective NSAIDs, with the possible exception of naproxen, increase cardiovascular (CV) hazard. Clinicians should assess not only patients' GI risk but also their CV risk before prescribing these drugs. Patients with low CV risk can be managed according to their GI risk-low-risk patients (without risk factors) receive nonselective NSAIDs, medium risk patients (1-2 risk factors) receive COX-2 inhibitors or nonselective NSAIDs plus a proton pump inhibitor (PPI) or misoprostol, whereas high-risk patients (multiple risk factors, previous ulcer complications, or concomitant anticoagulants) receive a COX-2 inhibitor plus a PPI or misoprostol. Among patients with high CV risk (e.g., prior cardiothrombotic events) who require NSAIDs, naproxen is preferred. These patients should receive a prophylactic PPI or misoprostol because the risk of ulcer bleeding is substantially increased with concomitant use of naproxen and low-dose aspirin. Substitution of clopidogrel for aspirin is not recommended in patients at risk for upper GI bleeding who require antiplatelet therapy. Patients with high GI and high CV risk should avoid NSAIDs and COX-2 inhibitors. If antiinflammatory analgesics are required, the choice of therapy depends on the relative importance of GI and CV risks of individual patients. Combination of naproxen, low-dose aspirin, and a PPI or misoprostol is recommended if CV risk is the major concern (e.g., recent myocardial infarction). In contrast, combination of low-dose COX-2 inhibitor, low-dose aspirin, and a PPI or misoprostol is preferred if GI risk outweighs CV risk (e.g., recent ulcer bleeding and stable CV disease).
The consequences of using widely available non-steroidal anti-inflammatory drugs (NSAIDs)

Joanna Synoweć,Katarzyna Pogorzelczyk,Marlena Robakowska,Daniel Ślęzak,Przemysław Żuratyński,Klaudiusz Nadolny,Wioletta Mędrzycka-Dąbrowska

DOI: https://doi.org/10.25121/mr.2018.21.3.281

2018-09-01

Medycyna Rodzinna

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used throughout the world due to their wide availability and a broad range of effects. Patients have easy access to these drugs in pharmacies and cosmetic shops, with the latter ones rarely having personnel qualified to provide advice on dosage. NSAIDs are usually administered to manage pain, fever and inflammation. They are used for conditions such as rheumatoid arthritis, oropharyngeal inflammations or in the treatment of chronic pain. Nevertheless, they are most often used for home treatment of common conditions, such as cold. However, NSAIDs can cause multiple adverse effects. They adversely affect the gastrointestinal tract, contribute to hypertension, show hepatotoxic properties, exacerbate respiratory diseases, induce allergies and haematological complications. Adverse effects may occur both due to overdose, as well as independently of the dose. The aim of this review is to present adverse effects of nonsteroidal anti-inflammatory drugs, the awareness of Poles concerning the use of NSAIDs, as well as measures to be taken in order to limit the adverse health consequences of the use of these drugs.
Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review

Rohab Sohail,Midhun Mathew,Zaroon Haider,Mansi Naria,Ayesha Habib,Waleed Razzaq Chaudhry,Anum Akbar,Khushbu K Patel,Srija A Reddy,Zain U Abdin

DOI: https://doi.org/10.7759/cureus.37080

2023-04-03

Cureus

Abstract:Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used for their anti-inflammatory, antipyretic, and analgesic properties. However, their use is often associated with gastrointestinal tract (GIT) side effects due to the inhibition of both cyclooxygenase (COX)-1 and COX-2 enzymes, leading to a decrease in gastroprotective prostaglandins (PG). To minimize these adverse effects, various approaches have been explored, including selective COX-2 inhibitors, NO-NSAIDs (nitric oxide-releasing NSAIDs), and dual COX/LOX (lipoxygenase) NSAIDs. However, the effects of these gastroprotective NSAIDs on the GIT and their efficacy remains uncertain. This review aims to provide an overview of the current understanding of the effects of traditional NSAIDs and gastroprotective NSAIDs on GIT. We discuss the underlying mechanisms of GIT damage caused by NSAIDs, including mucosal injury, ulceration, and bleeding, and the potential of gastroprotective NSAIDs to mitigate these effects. We also summarize recent studies on the efficacy and safety of various gastroprotective NSAIDs and highlight the limitations and challenges of these approaches. The review concludes with recommendations for future research in this field.
Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

Joshua Ide,Azza Shoaibi,Kerstin Wagner,Rachel Weinstein,Kathleen E. Boyle,Andrew Myers

DOI: https://doi.org/10.1007/s40266-024-01108-x

2024-03-25

Drugs & Aging

Abstract:Osteoarthritis (OA) is a major cause of chronic pain. Non-steroidal anti-inflammatory drugs (NSAIDs) are analgesics commonly used for musculoskeletal pain; however, NSAIDs can increase the risk of certain adverse events, such as gastrointestinal bleeding, edema, heart failure, and hypertension.

pharmacology & pharmacy,geriatrics & gerontology,gerontology
Management of High-risk Patients on Non-steroidal Anti-inflammatory Drugs or Aspirin

Francis K. L. Chan

DOI: https://doi.org/10.2165/00003495-200666001-00005

2006-01-01

Drugs

Abstract:Low-dose aspirin is increasingly used for the primary prevention of cardiovascular events. However, current evidence suggests that the gastrointestinal and other bleeding risks of aspirin probably outweigh its potential benefits in primary prevention. Various strategies have been proposed to reduce the gastrointestinal risk of aspirin, including gastroprotection with a proton pump inhibitor (PPI), eradication of Helicobacter pylori infection and replacing aspirin with other anti-platelet agents. Although co-therapy with a PPI and the eradication of H. pylori substantially reduce the risk of recurrent ulcer bleeding with aspirin, the replacement of aspirin by clopidogrel cannot be recommended to patients with a high gastrointestinal risk. Traditionally, strategies for the prevention of non-steroidal anti-inflammatory drug (NSAID)-induced ulcer complications included co-therapy with a gastroprotective agent and the substitution of cyclooxygenase (COX)-2 inhibitors for non-selective NSAID. Evidence emerged recently that COX-2 inhibitors and some non-selective NSAID increase cardiovascular risk. Before prescribing anti-inflammatory therapy, both gastrointestinal and cardiovascular risk factors of individual patients need to be evaluated. In patients with increased cardiovascular risk requiring anti-inflammatory analgesics, the combination of a non-selective NSAID, low-dose aspirin and a PPI is the preferred treatment.
Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

Moe H. Kyaw,Alaa Rostom,Katherine Muir,Catherine Dubé,Emilie Jolicoeur,Michel Boucher,Peter Tugwell,George Wells,Francis K.L. Chan

DOI: https://doi.org/10.1002/9781119211419.ch6

2019-01-01

Abstract:Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin (ASA) cause a variety of gastrointestinal (GI) toxicities, which are associated with excess utilization of health care resources at a substantial cost. NSAIDs inhibit the enzyme cyclo-oxygenase (COX). This enzyme exists in two isoforms: COX-1 and COX-2. This chapter addresses the issue of risk factors for NSAID-induced GI toxicity. In most clinical trials of NSAID prophylaxis, an endoscopic ulcer is defined as a break in the mucosal surface, usually greater than 3mm in diameter with some appreciable depth. The relative risk reduction in endoscopic gastric ulcers with misoprostol prophylaxis and with COX-2 inhibitors is about 80%. Helicobacter pylori contributes to an excess ulcer risk in NSAID naive patients. The chapter shows that the misoprostol is effective in the treatment of aspirin-induced enteropathy. It presents the evidence for the GI safety of COX-2 inhibitors and focuses on the following COX-2s: celecoxib, etoricoxib.
NSAID-induced gastrointestinal and cardiovascular injury.

Siew C Ng,Francis K L Chan

DOI: https://doi.org/10.1097/MOG.0b013e32833e91eb

2010-01-01

Current Opinion in Gastroenterology

Abstract:Purpose of review To review recent publications related to NSAID-induced adverse effects on the gastrointestinal and cardiovascular systems. Recent findings This paper explores novel mechanisms of NSAID-induced gastrointestinal injury, highlights new composite endpoints evaluating adverse events of NSAIDs in the entire gastrointestinal tract, and combines published data to establish evidence-based guidance on the best use of NSAIDs to achieve optimal clinical outcomes whilst minimizing cardiovascular and gastrointestinal injuries. Summary NSAIDs can induce peptic ulcers via epithelial cell membrane disruption and the renin angiotensin system, independent of the cyclooxygenase (COX) pathways, whereas mast cells and bile acid sensors may have a protective effect on NSAID-induced gastrointestinal damage. Patients with arthritis treated with a COX-2 inhibitor are less likely to develop upper and lower gastrointestinal complications than those who are treated with diclofenac plus a proton pump inhibitor (PPI). PPI therapy is recommended in patients receiving dual antiplatelet treatment but observational studies show that clopidogrel users taking PPIs have an increased risk of cardiovascular events. Until further reliable controlled data are available, this potential, but currently unproven, clinical interaction can be minimized by widely separating the dosing of clopidogrel and PPI. Histamine-2 antagonists may be an alternative to PPI for the prevention of peptic ulcers in patients taking low-dose aspirin.
The use of pain killers (NSAIDs) in athletes: how large is the risk?

Daniel Fitzpatrick,Todd Leckie,Gunnar Heine,Luke Hodgson

DOI: https://doi.org/10.1016/j.jsams.2024.11.010

IF: 4.597

2024-11-30

Journal of Science and Medicine in Sport

Abstract:Nonsteroidal anti inflammatory drug (NSAID) use is prevalent in sport however the risk associated with their use in athletes is not well understood. This review discusses the pharmacology of NSAIDs and the prevalence of their use in different sports and factors driving this. Use is very high in sports such as professional football and is sometimes used routinely without indication and without medical supervision. However there is a paucity of evidence in other sports. There is good evidence for use of NSAIDs following an acute injury but they may prevent normal tissue healing and remodelling if used longer term for MSK injuries. There are well known risks of cardiac, gastrointestinal and renal side effects but little specific data for athletes. Renal events are discussed in detail discussing the cumulative effect that NSAID use, dehydration and concurrent illness can have to produce significant renal and systemic insult. We then discuss a pragmatic prescribing model enabling clinicians to utilise the beneficial effects of these medications whilst minimising risks.

sport sciences

Non-steroidal anti-inflammatory drugs (NSAIDs) for musculoskeletal pain

NSAIDs, Risks, and Gastroprotective Strategies: Current Status and Future

Being on nonsteroidal anti-inflammatory drugs

Primer: Managing NSAID-induced Ulcer Complications—balancing Gastrointestinal and Cardiovascular Risks

Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations

Management of the upper gastrointestinal adverse effect of non-steroid anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) and organ damage: A current perspective

Management of Patients on Nonsteroidal Anti-inflammatory Drugs: A Clinical Practice Recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents

Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI

Non-steroidal anti-inflammatory drugs in sports medicine: guidelines for practical but sensible use

Relative Cardiovascular and Gastrointestinal Safety of Non-selective Non-steroidal Anti-inflammatory Drugs Versus Cyclo-oxygenase-2 Inhibitors

Management of NSAID-associated peptic ulcer disease

Pharmacoeconomics of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

The David Y. Graham Lecture: Use of Nonsteroidal Antiinflammatory Drugs in a COX-2 Restricted Environment

The consequences of using widely available non-steroidal anti-inflammatory drugs (NSAIDs)

Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDs) and Gastroprotective NSAIDs on the Gastrointestinal Tract: A Narrative Review

Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

Management of High-risk Patients on Non-steroidal Anti-inflammatory Drugs or Aspirin

Nonsteroidal Anti‐Inflammatory Drug‐Gastropathy and Enteropathy

NSAID-induced gastrointestinal and cardiovascular injury.

The use of pain killers (NSAIDs) in athletes: how large is the risk?